|
Office Locations:
|
300 Atlantic Street, Suite 600
Stamford, CT 06901
Phone: 203-487-8300
Fax: 203-487-8330
| |
|
|
|
|
Life Sciences & Healthcare
|
|
|
Healthcare Royalty Partners (CHRP) is a leading global healthcare private equity firm with over $5 billion in capital under management. The firm invests principally in commercial stage healthcare companies and products through the purchase of traditional passive royalties, the creation of Synthetic Royalties: and structured debt and equity instruments. Healthcare Royalty Partners seeks to structure investments that create long-term value for the firm's investors and its three distinct groups of counterparties: (i) healthcare product companies; (ii) academic, research and non-profit institutions; and (iii) inventors. The firm was founded in January 2007 and closed its inaugural fund, Healthcare Royalty Partners, L.P., in July 2008 with over $500 million in capital commitments. CHRP invests in healthcare companies and products across a broad range of therapeutic areas predominately in the U.S. and European Union. The firm targets investments between $20 million and $150 million, but will invest in excess of $100 million under certain circumstances. In December 2011, the firm closed the largest private equity fund dedicated to healthcare royalty investments, HealthCare Royalty Partners II, L.P. and an affiliated fund.
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|